NICE Reassessing Old CDF Drugs On Value-For-Money Basis – Some Fail
Executive Summary
NICE has begun the new HTA appraisal process for Britain’s remodeled Cancer Drugs Fund and has so far provisionally rejected three of the 35 drugs contained in the old CDF on cost-effectiveness grounds; two others got a thumbs up after their manufacturers offered further price cuts.
You may also be interested in...
Is ICER Too NICE? A Comparison Of Drug Assessments Programs
Drug companies are accusing the US Institute for Clinical and Economic Review of approaching cost effectiveness assessments in the same way as the UK National Health Service gatekeeper, the National Institute for Health and Care Excellence.
Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK
The promise seen in Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, should offset payer and HTA reluctance to use the monoclonal antibody despite its conditional EU marketing approval status.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.